KR20230159363A - Cdk 억제제의 공결정 - Google Patents

Cdk 억제제의 공결정 Download PDF

Info

Publication number
KR20230159363A
KR20230159363A KR1020237024297A KR20237024297A KR20230159363A KR 20230159363 A KR20230159363 A KR 20230159363A KR 1020237024297 A KR1020237024297 A KR 1020237024297A KR 20237024297 A KR20237024297 A KR 20237024297A KR 20230159363 A KR20230159363 A KR 20230159363A
Authority
KR
South Korea
Prior art keywords
compound
formula
fumarate salt
fumarate
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237024297A
Other languages
English (en)
Korean (ko)
Inventor
우데이 바트
라나딥 보칼리알
상가메시 에시와라파 바디게르
크리시나스와미 데바나탄
Original Assignee
오리진 온콜로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오리진 온콜로지 리미티드 filed Critical 오리진 온콜로지 리미티드
Publication of KR20230159363A publication Critical patent/KR20230159363A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237024297A 2020-12-18 2021-12-17 Cdk 억제제의 공결정 Pending KR20230159363A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041055174 2020-12-18
IN202041055174 2020-12-18
PCT/IB2021/061895 WO2022130304A1 (en) 2020-12-18 2021-12-17 Cocrystal of a cdk inhibitor

Publications (1)

Publication Number Publication Date
KR20230159363A true KR20230159363A (ko) 2023-11-21

Family

ID=80001496

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237024297A Pending KR20230159363A (ko) 2020-12-18 2021-12-17 Cdk 억제제의 공결정

Country Status (17)

Country Link
US (1) US20240059669A1 (cg-RX-API-DMAC10.html)
EP (1) EP4263534A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023554492A (cg-RX-API-DMAC10.html)
KR (1) KR20230159363A (cg-RX-API-DMAC10.html)
CN (1) CN116685326A (cg-RX-API-DMAC10.html)
AU (1) AU2021402415A1 (cg-RX-API-DMAC10.html)
CA (1) CA3202198A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023001753A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023009368A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230261A (cg-RX-API-DMAC10.html)
DO (1) DOP2023000126A (cg-RX-API-DMAC10.html)
EC (1) ECSP23054131A (cg-RX-API-DMAC10.html)
IL (1) IL303738A (cg-RX-API-DMAC10.html)
MX (1) MX2023007218A (cg-RX-API-DMAC10.html)
PE (1) PE20231441A1 (cg-RX-API-DMAC10.html)
TW (1) TW202241881A (cg-RX-API-DMAC10.html)
WO (1) WO2022130304A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4232010A4 (en) * 2020-10-22 2024-09-04 Aurigene Oncology Limited CANCER THERAPY USING A CDK7 INHIBITOR IN COMBINATION WITH AN ANTI-MICROTUBULE AGENT
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
CN118772106A (zh) * 2024-06-07 2024-10-15 山东大学 伊马替尼-没食子酸共晶、其溶剂化物、制备方法和应用
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3302448T3 (da) * 2015-06-04 2024-02-05 Aurigene Oncology Ltd Erstattede heterocyclylafledninger som cdk-inhibitore

Also Published As

Publication number Publication date
WO2022130304A1 (en) 2022-06-23
PE20231441A1 (es) 2023-09-14
CL2023001753A1 (es) 2024-02-02
ECSP23054131A (es) 2023-09-29
JP2023554492A (ja) 2023-12-27
TW202241881A (zh) 2022-11-01
CN116685326A (zh) 2023-09-01
AU2021402415A1 (en) 2023-07-06
CR20230261A (es) 2023-10-04
CO2023009368A2 (es) 2023-09-29
US20240059669A1 (en) 2024-02-22
DOP2023000126A (es) 2023-11-30
CA3202198A1 (en) 2022-06-23
IL303738A (en) 2023-08-01
MX2023007218A (es) 2023-07-27
EP4263534A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
US20240059669A1 (en) Cocrystal of a cdk inhibitor
CN112839715B (zh) 抑制shp2活性化合物的制造方法
JP6882299B2 (ja) 多環式tlr7/8アンタゴニスト及び免疫障害の治療におけるそれらの使用
CN111201223B (zh) SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
CN120548318A (zh) Kras g12d抑制剂和其用途
CN121752574A (zh) Kras抑制剂和其用途
CN120882724A (zh) Kras g12d抑制剂和其用途
WO2021027911A1 (zh) 新型螺环类K-Ras G12C抑制剂
JP6097289B2 (ja) セリン/スレオニンキナーゼインヒビターとしてのキナゾリン化合物
WO2021057867A1 (zh) 一类基于有机胂的cdk抑制剂及其制备方法和用途
WO2021098859A1 (zh) 氮杂七元环类抑制剂及其制备方法和应用
TW201718490A (zh) Lsd1抑制劑之鹽
JP5937112B2 (ja) 選択的fak阻害剤
TW201620896A (zh) 苯并咪唑衍生物及其醫藥組合物及使用方法
CN117203208A (zh) 靶向活化与失活态kras g12d的抑制剂
JP2021523208A (ja) ピリミジン誘導体の医薬塩及び障害の処置方法
WO2022188889A1 (zh) 作为parp7抑制剂的化合物
WO2020259703A1 (zh) 一种吡唑酮并嘧啶类化合物、其制备方法及应用
JP2022549353A (ja) プロテインキナーゼc(pkc)に作用するジテルペノイド化合物
JP2012255038A (ja) 異常な細胞増殖の治療用のピリミジン誘導体
US20230174545A1 (en) Heterocyclic compounds as bet inhibitors
CN116917273A (zh) 作为dnmt1抑制剂的经取代的吡啶
CA3188173A1 (en) Novel compound, and pharmaceutical composition for preventing or treating resistant cancer, comprising same
EA050691B1 (ru) Сокристалл ингибитора cdk
HK40099717A (en) Cocrystal of a cdk inhibitor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230717

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241217

Comment text: Request for Examination of Application